Stocktoria
Insight Molecular Diagnostics Inc. IMDX
Nasdaq · XNAS · stock · In Vitro & In Vivo Diagnostic Substances · website · IPO 2015-12-30
Insight Molecular Diagnostics Inc. statistics & valuation
Market cap$174.4M
P / S43.0×
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Gross margin | 56.7% | 39.3% | 27.5% | -1.9% | 64.6% |
| Operating margin | -1260.8% | -3245.1% | -1672.4% | -1878.6% | -2444.3% |
| Net margin | -1238.5% | -3225.0% | -1848.4% | -7609.8% | -2916.2% |
| FCF margin | -625.6% | -1127.3% | -1570.6% | -5209.6% | -1737.4% |
| Return on assets | -195.0% | -172.9% | -37.1% | -72.8% | -40.2% |
| Return on equity | 159.6% | 494.2% | -135.7% | -212.6% | -98.3% |
| Current ratio | 1.27 | 1.62 | 1.49 | 2.11 | 2.77 |
| Revenue growth | 115.6% | 25.1% | 56.9% | -56.4% | 80.8% |
Source: SEC EDGAR filings · CIK 0001642380 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.